Biomedical Engineering Reference
In-Depth Information
References
Abal M, Andreu JM, Barasoain I. 2003. Taxanes microtubule and centrosome targets, and cell cycle
dependent mechanisms of action.
Curr Cancer Drug Targets
3:193-203.
Acharya G and Park K. 2006. Mechanisms of controlled drug release from drug-eluting stents.
Adv
Drug Deliv Rev
58:387-401.
Alexis F, Venkatraman SS, Rath SK, Boey F. 2004. In vitro study of release mechanisms of paclitaxel and
rapamycin from drug-incorporated biodegradable stent matrices.
J Control Release
98:67-74.
American Heart Association. 2003. Heart Disease and Stroke Statistics—2004 Update. Dallas, TX:
American Heart Association.
Am. Soc. Health Syst. Pharm. 1989. AHFS Drug Information, pp.1075-1086. Bethseda, MD: Am. Soc.
Health Syst. Pharm.
Aoki J, Serruys PW, van Beusekom H et al. 2005. Endothelial progenitor cell capture by stents coated
with antibody against CD34: The HEALING-FIM(Healthy Endothelial Accelerated Lining
Inhibits Neointimal Growth-First In Man) registry.
J Am Coll Cardiol
45:1574-1579.
Balmer F, Rotter M, Togni M
et al. 2005. Percutaneous coronary interventions in Europe 2000.
Int J
Cardiol
101:457-463.
Bartorelli AL, Trabattoni D, Fabbiocchi F
et al. 2003. Synergy of passive coating and target drug deliv-
Synergy of passive coating and target drug deliv-
ery: The tacrolimus-eluting Janus Carbostent.
J Interv Cardiol
16(6):499-505.
Beijk MAM, Klomp M, Verouden NJW
et al. 2009. Genous™ endothelial progenitor cell capturing stent
vs the Taxus Liberté stent in patients with de novo coronary lesions with a high-risk of coronary
restenosis: a randomized, single-centre, pilot study.
Eur Heart J
in press.
Billich A, Aschauer H, Aszódi A et al. 2004. Percutaneous absorption of drugs used in atopic eczema:
pimecrolimus permeates less through skin than corticosteroids and tacrolimus.
Int J Pharm
269:9-35.
Caves JM and Chaikof EL. 2006. The evolving impact of microfabrication and nanotechnology on
stent design.
J Vasc Surg
44:1363-1368.
Chang TY, Yadav VG, De Leo S
et al. 2007. Cell and protein compatibility of Parylene-C surface.
Langmuir
23:11718-11725.
Chadwick DR. 2006. The smaller contenders for the DES market.
Cath Lab Digest
14:1.1.
Chen MC, Liang HF, Chiu YL
et al. 2005. A novel drug-eluting stent spray-coated with multi-layers
of collagen and sirolimus.
J Control Release
108:178-189.
Chen SL and Sheiban I. 2009. Dedicated bifurcation stents strategy.
Interv Cardiol
4:70-72.
Chevalier B, di Mario C, Neumann FJ et al. 2008. A randomized, controlled, multicenter trial to evalu-
A randomized, controlled, multicenter trial to evalu-
ate the safety and efficiency of Zotarcrolimus-versus paclitaxel-eluting stents in de novo occlu-
sive lesions in coronary arteries: The ZoMaxx I trial.
J Am Coll Cardiol Intv
1:524-532.
Chudzik SJ, Anderson AB, Chapp RA et al. 2001. Kloke TM: Bioactive agent release coating. United
States Patent, Patent No. US 6214901B1, April 10, 2001.
Co M, Tay E, Lee CH
et al. 2008. Use of endothelial progenitor cell capture stent (Genous Bio-
Engineered R Stent) during primary percutaneous coronary intervention in acute myocardial
infarction: Intermediate- to long-term clinical follow-up.
Am Heart J
155:128-132.
Colombo A and Airoldi F. 2003. Passive coating: The dream does not come true.
J Invas Cardiol
15(10):566-567.
Colombo A, Drzewiecki J, Banning A
et al. 2003. Randomized study to assess the effectiveness of
slow-and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions.
Circulation
108:788-794.
Cook S and Windecker S. 2009. Early stent thrombosis: Past, present, and future.
Circulation
119:657-659.
Cuvelier D, Vezy C, Viallat A et al. 2004. Mimicking cell/extracellular matrix adhesion with lipid
membranes and solid substrates: Requirements, pitfalls and proposals.
J Phys Condens Matter
16:S2427-S2437.
008. A randomized, controlled, multicenter trial to evalu-
